---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-24-000078"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:20:33.702812+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Editas reni-cel RUBY trial: 18 SCD patients VOE-free; EdiTHAL: 7 TDT patients transfusion-free

## Summary
- 18 SCD patients free of vaso-occlusive events post-reni-cel (follow-up 2.4-22.8 months); mean total Hb >14 g/dL, HbF >40%.
- 7 TDT patients transfusion-free for 4.1-12.8 months; mean total Hb 12.1 g/dL at month 6, HbF 10.9 g/dL.
- No serious adverse events related to reni-cel in either trial; safety profile consistent with myeloablative conditioning.
- Median neutrophil engraftment 23 days (SCD and TDT); platelet engraftment 24 days (SCD), 38 days (TDT).
- Further clinical update from both trials expected by year-end 2024.

## SEC filing metadata
- accession: 0001650664-24-000078
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000078/0001650664-24-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000078/edit-20240614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-24-000078
- JSON: https://secwatch.observer/filing/0001650664-24-000078.json
- Plain text: https://secwatch.observer/filing/0001650664-24-000078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.